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Abstract
Objective: The purpose of this paper is to report a patient with otherwise unexplained cerebellar ataxia with serum
antibodies against contactin-associated protein-2 (CASPR-2) and provide a detailed description of the composition
of cellular infiltrates in the cerebrospinal fluid (CSF) compared to the peripheral blood (PB). CASPR-2 antibodies
strongly labeling axons of cerebellar granule neurons have recently been identified in sera from nine patients with
otherwise unexplained progressive cerebellar ataxia with mild to severe cerebellar atrophy.
Design: This is a report of a single case.
Methods: The study methods used were neurologic examination, magnetic resonance imaging,
fluorodeoxyglucose positron emisson tomography, lumbar puncture and multicolor flow-cytometry.
Results: A 23-year-old Caucasian male presented with a two-year history of a progressive cerebellar and brainstem
syndrome. Magnetic resonance imaging (MRI) showed pronounced cerebellar atrophy, especially of the medial parts of
the hemispheres and the vermis. Cerebral fluorodeoxyglucose positron emission tomography (FDG-PET) showed
pronounced hypometabolism of the whole cerebellum. CASPR-2 antibodies were detected in the serum but not the CSF,
and none of the staging and laboratory assessments revealed other causes of progressive cerebellar degeneration.
Interestingly, flow-cytometry of the CSF as compared to the PB showed increased fractions of CD138+ plasma cells as well
as human leukocyte antigen (HLA)-DR+ CD8+ T cells suggesting that both B cells and CD8+ T cells were preferentially
recruited to and activated within the CSF- (and putatively central nervous system (CNS)-) compartment.
Conclusion: We confirm the association of CASPR-2 serum antibodies with cerebellar ataxia and provide the first
evidence for a combined humoral and cellular immune response in this novel antibody-associated inflammatory CNS
disease.
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Background
Antibodies to the complex of voltage-gated K+ channels
(VGKC) and associated neuronal membrane proteins
(contactin-associated protein-2 (CASPR-2; axon);
contactin-2 (ensheathing glial cells); leucine-rich glioma
inactivated 1 protein (LGI-1; synapse)) are detected in
the sera of patients with peripheral nerve hyperexcitabil-
ity (acquired neuromyotonia), Morvan's disease and lim-
bic encephalitis [1-3].
Recently, CASPR-2 antibodies strongly labeling axons of
cerebellar granule neurons have been identified in sera
from nine patients with otherwise unexplained progressive
cerebellar ataxia [4]. In these patients, MRI was unremark-
able or showed mild to severe cerebellar atrophy. Cerebro-
spinal fluid (CSF) was only examined in three of nine
patients and was reported to be normal. Electroencephalog-
raphy and electromyography were also unremarkable.
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Using multicolor flow cytometry, we add excessive cel-
lular CSF and peripheral blood (PB) analysis of another




MRI was performed on 3-tesla scanners. Diffusion
weighted imaging (DWI) with calculation of ADC-map,
axial and coronar T1-SE before and after application of
gadolinium, axial and coronar FLAIR-, axial and saggital
T2-FFE- and T2-TSE sequences were performed.
Multicolor flow cytometry
Flow cytometry was performed on a NaviosTM Flow
Cytometer (Beckman Coulter, Krefeld, Germany) and
results were analyzed using the Kaluza Software 1.1
(Beckman Coulter, Inc., Brea, CA, USA) as previously
described [5]. Reference values for the leukocyte subsets of
the peripheral blood and CSF were gained from 17 healthy
individuals and presented as mean± standard deviation.
Case presentation
A 23-year-old Caucasian male complained of progressive
imbalance of gait, slurred speech, tremor of the upper and
lower legs, and double vision two years prior to admission.
Severe pancerebellar and brainstem dysfunction was evi-
dent in the neurological examination. An initial cerebral
magnetic resonance imaging (MRI), performed approxi-
mately six months after symptom onset, was unremark-
able (Figure 1A, C), but follow-up studies revealed
pronounced cerebellar atrophy, especially of the medial
parts of the hemispheres and the vermis (two years after
symptom onset) (Figure 1B, D). At that stage, cerebral
fluorodeoxyglucose positron emission tomography (FDG-
PET) showed pronounced hypometabolism of the whole
cerebellum (Figure 1E, arrow) consistent with the clinical
presentation. Considerable hereditary, metabolic, toxic,
infectious and autoimmune causes of progressive cerebel-
lar atrophy were absent. Electroencephalography, somato-
sensory and motor evoked potentials, peripheral nerve
conduction studies and electromyography were all unre-
markable. Standard CSF analysis revealed only minor in-
flammatory changes with a mild lymphomonocytic
pleocytosis (6/μl), slightly elevated protein (610 mg/l)
with an intact blood-CSF barrier function (albumin-ratio
5.1 x 10-3), an intrathecal IgG (35%) and IgM (10%) syn-
thesis and four CSF-specific oligoclonal bands. Glucose
and lactate levels were normal.
A computed tomography (CT)-scan of the chest and
abdomen showed a nodular lesion of the apical thymus
(Figure 1F, arrow). Subsequent thymectomy demon-
strated hyperplasia of the thymus but no thymoma. A
FDG-PET-CT of the whole body showed no evidence of
a malignant tumor (not shown). Immunofluorescence
testing of serum but not CSF revealed granular staining
on non-permeabilized rodent hippocampal and cerebel-
lar slices, and subsequent immunofluorescense testing in
a cell-based assay showed positive antibody reactivity
with CASPR-2 but not LGI-1 (Euroimmun, Lübeck,
Germany).
Flow cytometry [5] of the peripheral blood (Figure 1G,
upper panels, PB) revealed a normal CD4/CD8 ratio of
2.0 (normal 3.8 ± 1.5). The fractions of activated CD4+
HLA-DR+ T cells (7.0%, normal 3.9 ± 1.7%) and CD8+
HLA-DR+ T cells (12.2%, normal 6.2 ± 3.0%) were only
slightly elevated in the PB. Likewise, the fraction of
CD19+ B cells (9.4%, normal 12.7 ± 5.4%) and CD138+
plasma cells (0.16%, normal 0.17 ± 0.14%) were normal
in the PB.
In contrast, flow cytometry of the CSF (Figure 1G,
lower panels, CSF) revealed predominantly CD3+ CD56-
T cells (95%) with a low CD4/CD8 T cell ratio of 2.2
(normal 2.9 ± 1.8). This was due to a relatively small
CD4+ T cell fraction (63.8%; normal 73.8 ± 9.5%) to-
gether with a relatively large CD8+ T cell fraction
(32.1%; normal 22.4 ± 9.3%). Moreover, numbers of acti-
vated CD4+ HLA-DR+ T cells (18.3%, normal 6.4 ± 3.5%),
but especially CD8+ HLA-DR+ T cells (70.6%, normal
25.7 ± 9.9%), were strongly increased in the CSF. Like-
wise, the fraction of CD19+ B cells (3.5%, normal
0.8 ± 0.8%) was elevated in the CSF and accompanied by
strongly increased numbers of CD138+ plasma cells
(1.3%, normal 0.02 ± 0.09%). However, considering
CD138+ plasma cells as activated B cells only about 26%
of all B cells displayed an activated phenotype.
Hence, although standard CSF analysis showed only
very mild inflammatory changes, detailed cellular CSF
assessment by multicolor flow cytometry clearly revealed
that as compared to controls, cytotoxic CD8+ T cells and
B cells were preferentially recruited to the CSF- (and pu-
tatively CNS-) compartment in CASPR-2 antibody asso-
ciated cerebellar ataxia as suggested recently [6-9].
However, as the fraction of B cells is small compared to
the fraction of CD8+ T cells, it may in general be subject
to a larger margin of experimental variance. Moreover, a
majority of about 70% of the cytotoxic CD8+ T cells dis-
played an activated phenotype (that is, HLA-DR expres-
sion), whereas only a minority of about 26% of the B
cells displayed an activated phenotype (that is, CD138
expression). Thus, we consider the activation of cyto-
toxic CD8+ T cells within the CSF (and putatively CNS)
stronger than that of CD19+ B cells.
The patient received intravenous methylprednisolon
pulse-therapy together with plasma-exchange, which had
no significant clinical effect. Three months later an
immunoadsorption was applied, which, together with
thymectomy, led to some deceleration of disease
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progression. Currently, the patient is undergoing regular
immunoadsorption, but will receive rituximab and/or
cyclophosphamide in case of further progression.
Ethics approval
The use of human subjects for this study was approved
by the local ethics committee at the University of Mün-
ster, Germany.
Discussion
Antibodies to the complex of voltage-gated K+ channels
(VGKC) are predominantly of the IgG4 subclass sup-
posed to reversibly disrupt the respective protein com-
plexes leading to altered synaptic transmission and
plasticity as well as neuronal excitability and axonal con-
duction without overt cytotoxicity [1,10].
This concept is consistent with a good response, espe-
cially to antibody-depleting therapies, and a rather strong
correlation between serum antibody levels and clinical dis-
ease course, at least at early disease stages [1,10]. At later
disease stages, intrathecal antibody production and main-
tenance of the disease process despite systemic immuno-
therapies (with a weak impact on the CNS compartments)
has been postulated to be due to the infiltration of B cells
and plasma cells into the CNS parenchyma as well as
neighboring CSF compartments in patients with N-
Methyl-D-Aspartate (NMDA) receptor encephalitis [9].
However, in the CNS specimen of patients with VGKC,
complex encephalitis antibody- and complement-
mediated neuronal cell death (mostly in the absence of B
cells and plasma cells) together with an increased fraction
of parenchymal CD8+ T cells (about 50% of all T cells) has
been observed, recently [8]. Although direct opposition of
C8+ T cells to neurons was not detected by histological
techniques, many of these cells displayed a functionally
activated phenotype (that is, expression of granzyme B),
Figure 1 Humoral and cellular immune response within the CSF- (and putatively central nervous system (CNS)-) compartment. The
initial cerebral MRI about half a year after symptom onset was unremarkable (A, FLAIR-weighted images, C, T2 weighted images). Two years after
symptom onset a pronounced cerebellar atrophy, especially of the medial parts of the hemispheres and the vermis, was evident (B, FLAIR-
weighted images, D, T2 weighted images), and cerebral FDG-PET showed pronounced hypometabolism of the whole cerebellum (E, arrow). A
computed tomography (CT)-scan of the chest showed a nodular lesion of the apical thymus (F, arrow). Flow-cytometry of the cerebrospinal fluid
(G, lower panels; H, open red circles; CSF) as compared to the peripheral blood (G, upper panels; H, filled red circles; PB) and to a total of 17
healthy controls (H, filled and empty black circles) showed a low CD4/CD8 ratio together with increased fractions of activated HLA-DR+ CD4+ T
cells and especially HLA-DR+ CD8+ T cells as well as CD19+ B cells and CD138+ plasma cells suggesting that both B cells and CD8+ T cells were
preferentially recruited to and activated within the cerebrospinal fluid-compartment.
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and neurons at inflammatory sites expressed major histo-
campatibility class I (MHC I) molecules enabling them to
present autoantigens [8]. Hence, CD8+ T cell-mediated
neurotoxcity together with antibody-mediated cytotoxicity
may contribute to an increasing resistance to systemic im-
munotherapies at later disease stages as observed in our
patient.
Generally, both effector arms of the adaptive immune
response may be activated irrespective of whether the
respective neuronal antigen (or its antigenic epitope) is
localized on the surface membrane or the interior cellu-
lar compartments of the neuron [3]. However, plasma
cell-derived antibodies may only bind to antigens
exposed on the surface membrane, whereas cytotoxic
CD8+ T cells usually recognize antigens from interior
cell compartments following their MHC I-bound pres-
entation on the surface membrane. Whether peptides
derived from neuronal surface antigens, such as compo-
nents of the VGKC complex, are also presented to cyto-
toxic CD8+ T cells in the context of MHC I molecules
enabling them to clonally expand and contribute to
neuronal dysfunction needs further investigation [11-
13]. Alternatively, CD8+ T cells specific for intracelluar
neuronal antigen might become activated secondary to
antibody-mediated neuronal damage in VGKC complex
encephalitis.
Conclusion
We confirm the association of serum antibodies to
CASPR-2 with otherwise unexplained cerebellar ataxia
of non-paraneoplastic origin. By detailed analysis of the
PB and CSF, our case provides first evidence for a com-
bined cellular and humoral immune response in this
novel antibody-associated inflammatory CNS disease.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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